Expand AIM Menu
AIM MENU

AIM Stock Summary and Trading Ideas (Aim Immunotech | AMEX:AIM)

Charts for Today's Stock Price and Implied Volatility in Aim Immunotech

17-Jan-2025

Stock Price & Volume | Full Chart

Sentiment

News

No headlines found.

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

Globe Newswire (Wed, 15-Jan 9:05 AM ET)

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Globe Newswire (Tue, 17-Dec 4:45 PM ET)

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

Business Wire (Tue, 17-Dec 3:10 PM ET)

AIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy Card

Business Wire (Mon, 16-Dec 8:00 AM ET)

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

Globe Newswire (Sat, 14-Dec 4:54 PM ET)

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members

Business Wire (Thu, 12-Dec 3:00 PM ET)

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Globe Newswire (Thu, 12-Dec 9:00 AM ET)

Kellner Group Announces Support from Another Former AIM Senior Executive

Globe Newswire (Thu, 12-Dec 8:16 AM ET)

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell

Business Wire (Tue, 10-Dec 10:20 AM ET)

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

Globe Newswire (Tue, 10-Dec 7:30 AM ET)

Trading Statistics

Key Ratios

Aim Immunotech (AIM) Frequently Asked Questions

What does Aim Immunotech do?

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

What symbol and exchange does Aim Immunotech shares trade?

Aim Immunotech trades on the AMEX stock market under the symbol AIM.

What is Aim Immunotech stock price doing today?

As of January 17, 2025, AIM stock price climbed to $0.21 with 891,765 million shares trading.

How much is Aim Immunotech worth?

AIM has a market cap of $13.64 million. This is considered a Sub-Micro Cap stock.

How much money does Aim Immunotech make?

Last quarter Aim Immunotech reported $35,000 in Revenue and -$.06 earnings per share. This beat revenue expectation by $23,330 and exceeded earnings estimates by $.03.

What is the highest and lowest price Aim Immunotech traded in the last 3 year period?

In the last 3 years, AIM traded as high as $1.38 and as low as $.16.

What are the top ETFs holding Aim Immunotech?

The top ETF exchange traded funds that AIM belongs to (by Net Assets): VTI, VXF.

Is Aim Immunotech (AIM) a good investment?

AIM has underperformed the market in the last year with a price return of -50.3% while the SPY ETF gained +28.0%. AIM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.5% and -8.4%, respectively, while the SPY returned +3.0% and +1.0%, respectively.

What are the support and resistance levels for Aim Immunotech (AIM)?

AIM support price is $.19 and resistance is $.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM shares will trade within this expected range on the day.